215303-72-3

中文名称 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑

英文名称 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol

CAS 215303-72-3

分子式 C27H24FN3O

分子量 425.5

MOL 文件 215303-72-3.mol

更新日期 2023/10/11 16:18:38

215303-72-3 结构式

基本信息物理化学性质 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑价格(试剂级) 常见问题列表

基本信息

中文别名

4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑

英文别名

CS-1470
RWJ 67657
JNJ 3026582
RWJ-67657
JNJ-3026582
RWJ-67657
RWJ-67657
RWJ-67657
4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-phenylpropyl)-5-(4-Pyridyl)iMidazole
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol
3-Butyn-1-ol, 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol ISO 9001：2015 REACH

所属类别

医药中间体：羟基吡啶

物理化学性质

熔点124℃

沸点611.8±65.0 °C(Predicted)

密度1.14±0.1 g/cm3(Predicted)

储存条件Store at RT

溶解度≤10mg/ml in ethanol;5mg/ml in DMSO;2mg/ml in dimethyl formamide

酸度系数(pKa)14.37±0.10(Predicted)

形态黄色粉末

4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-15505	4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657	215303-72-3	5mg	800元
2024/04/30	HY-15505	4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657	215303-72-3	10mM * 1mLin DMSO	880元
2024/04/30	HY-15505	4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657	215303-72-3	10mg	1280元

常见问题列表

生物活性

RWJ-67657 (JNJ 3026582) 是一种具有口服活性的选择性 p38α 和 p38β 抑制剂，IC50 分别为 1 和 11 μM。RWJ-67657 对 p38γ 和 p38δ 无活性，是心脏保护剂，具有抗炎和抗肿瘤活性。

靶点

p38α

1 μM (IC ₅₀ )

p38β

11 μM (IC ₅₀ )

体外研究

RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC ₅₀ of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC ₅₀ value of 13 nM.
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells.

Cell Proliferation Assay

Cell Line:	MCF-7 breast carcinoma cells
Concentration:	10 μM
Incubation Time:	24 hours
Result:	Decreased colony formation.

体内研究

RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration.
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke.

Animal Model:	The db/db mice (male, 8 weeks old) with EPCs
Dosage:	50 mg/kg
Administration:	Administered orally; once per day for 7 consecutive days
Result:	Increased angiogenesis and neurogenesis of diabetic mice after cotreatment with EPCs transplantation.